Vorasidenib-VORANIGO Chinese instruction manual complete version

Vorasidenib (trade name Voranigo®) is a selective, oral, once-daily IDH1/2 mutation inhibitor indicated primarily for the treatment of adults and 12 following surgery (including biopsy, partial or total resection) Low-grade glioma (LGG) in children aged years and older, and the tumor has a sensitive IDH1 or IDH2 mutation. The drug selectively inhibits the activity of IDH1/2 mutant enzyme and blocks the abnormal accumulation of 2‑hydroxyglutarate (2‑HG) in tumor cells, thereby slowing down tumor proliferation and delaying disease progression. This mechanism is clinically considered to have the advantages of strong targeting and controllable toxicity, providing a new treatment option for patients with relapsed or refractory LGG after traditional surgery, radiotherapy and chemotherapy. Vorasidenib 's approval was primarily based on the results of II phase clinical studies, including the INDIGO study, which showed that the drug was effective in IDH mutations LGG It can significantly prolong progression-free survival in patients with good safety profile.

In terms of usage and dosage, the recommended adult dose of Voranigo is 40 mg taken orally once daily. For adolescent patients weighing 40 kg or less, the recommended dose is 20 mg daily, with adult doses available once body weight exceeds 40 kg . The dosing time should be fixed and taken at the same time every day. It can be taken with food to improve compliance, but it does not need to be on an empty stomach. If the patient misses a dose, he should take it as soon as possible within 6 hours; if it exceeds 6 hours, skip the current dose and take it at the next regular time. Do not double the dose. The treatment cycle generally continues until the imaging or clinical progression of the disease, or the occurrence of intolerable adverse reactions. Before using this drug, the tumor IDH1/2 mutation status must be confirmed, and patients who are allergic to the drug ingredients must be excluded.

The safety profile of Voranigo is generally good but requires close monitoring. Common adverse reactions include fatigue, headache, diarrhea, nausea, musculoskeletal pain and epileptic seizures. In terms of laboratory abnormalities, elevated transaminases, elevated serum bilirubin, and hematological abnormalities (such as neutropenia, anemia) are the main monitoring indicators. Grade 3/4Adverse events are relatively rare but may still lead to short-term discontinuation or dose adjustment. Liver function monitoring is particularly critical. Liver function assessment needs to be carried out before treatment. It is recommended to monitor every two weeks in the initial stage of treatment, and then monthly for at least the first two years to detect and deal with liver toxicity in a timely manner. If a significant increase in ALT or AST occurs, the dose should be adjusted according to the guidelines or the medication should be suspended, and if necessary, the medication should be permanently discontinued.

For patients during childbearing period, Voranigo has potential reproductive toxicity and should not be used by pregnant and lactating women. Women of childbearing age need to take effective contraceptive measures during treatment and for at least three months after stopping the drug, and male partners also need to use barrier contraception. In terms of drug metabolism, Vorasidenib is mainly metabolized by the liver CYP1A2 and CYP3A , so it should be avoided with potent CYP1A2 Inhibitors or inducers are used together to prevent abnormal fluctuations in drug concentration. Oral hormonal contraceptives may be affected during use, requiring additional barrier contraceptive measures. There are insufficient research data in patients with renal insufficiency and severe hepatic impairment, so use with caution.

In terms of clinical experience, since Voranigo is an oral drug and is administered once a day, its treatment is more convenient, reducing the frequency of patients traveling to and from medical institutions, and has less impact on the quality of life of children and adolescent patients in particular. During the course of treatment, more than half of patients can achieve disease stabilization or remission, which means there is a greater chance of symptom improvement and improvement in daily activities. Although side effects such as headache, fatigue, or mild rash exist, most can be controlled through symptomatic treatment, dose adjustment, or short-term discontinuation. Patients and their families need to maintain close communication with the medical team during use and report any abnormal symptoms in a timely manner so that potential risks can be dealt with in a timely manner.

In terms of long-term management, Voranigo should be used in conjunction with routine imaging follow-up and laboratory monitoring to ensure sustained efficacy while minimizing adverse reactions. During drug treatment, it is important to educate patients and their families about medication compliance, identification of potential side effects, and emergency treatment measures. For children and adolescents, psychosocial support cannot be ignored, including guidance on changes in appearance, fatigue, and adaptation to school life.

Overall, Voranigo provides a new option for targeted therapy for patients with low-grade gliomas with IDH1/2 mutations. Its targeting mechanism is clear, effective and easy to use. Through standardized dose management, strict monitoring protocols and multidisciplinary collaboration, clinical benefits can be maximized and toxicity controlled. In the future, with the accumulation of more long-term follow-up data and real-world evidence, Voranigo is expected to further clarify its effectiveness in different age groups and different molecular types.LGG The efficacy, safety and usage strategies in patients provide continuous and personalized treatment options for such patients.

Reference materials:https://www.drugs.com/